These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. Neuropsychological impairment among asymptomatic HIV-positive former intravenous drug users. Rodríguez Salgado D; Rodríguez Alvarez M; Seoane Pesqueira G Cogn Behav Neurol; 2006 Jun; 19(2):95-104. PubMed ID: 16783132 [TBL] [Abstract][Full Text] [Related]
4. Immune serum markers and CD4 cell counts in HIV-infected intravenous drug users. Chaisson RE; Taylor E; Margolick JB; Muñoz A; Solomon L; Cohn S; Nelson KE; Vlahov D J Acquir Immune Defic Syndr (1988); 1992; 5(5):456-60. PubMed ID: 1348535 [TBL] [Abstract][Full Text] [Related]
5. Relationship of CD4 counts to neurophysiological function in HIV-1--infected homosexual men. Boccellari AA; Dilley JW; Yingling CD; Chambers DB; Tauber MA; Moss AR; Osmond DH Arch Neurol; 1993 May; 50(5):517-21. PubMed ID: 8098207 [TBL] [Abstract][Full Text] [Related]
6. HTLV-II/HIV-1 coinfection and risk for progression to AIDS among intravenous drug users. Visconti A; Visconti L; Bellocco R; Binkin N; Colucci G; Vernocchi L; Amendola M; Ciaci D J Acquir Immune Defic Syndr (1988); 1993 Nov; 6(11):1228-37. PubMed ID: 7901382 [TBL] [Abstract][Full Text] [Related]
7. Serum beta 2-microglobulin in intravenous drug users and its correlation with human immunodeficiency virus infection. Chironna M; Fanelli M; Potenza D; Serio G; Quarto M Int J Clin Lab Res; 1994; 24(2):90-3. PubMed ID: 7919434 [TBL] [Abstract][Full Text] [Related]
8. Serum beta 2-microglobulin and prediction of progression to AIDS in HIV-infected injection drug users. Zabay JM; Sempere JM; Benito JM; Gonzalez B; Obregón E; Díez J; Fernández-Cruz E J Acquir Immune Defic Syndr Hum Retrovirol; 1995 Mar; 8(3):266-72. PubMed ID: 7859138 [TBL] [Abstract][Full Text] [Related]
9. Neuropsychological impairment-associated visual field deficits in HIV infection. HNRC Group. HIV Neurobehavioral Research Center. Plummer DJ; Marcotte TD; Sample PA; Wolfson T; Heaton RK; Grant I; Freeman WR Invest Ophthalmol Vis Sci; 1999 Feb; 40(2):435-42. PubMed ID: 9950603 [TBL] [Abstract][Full Text] [Related]
10. Factors affecting cognitive functioning in a sample of human immunodeficiency virus-positive injection drug users. Margolin A; Avants SK; Warburton LA; Hawkins KA AIDS Patient Care STDS; 2002 Jun; 16(6):255-67. PubMed ID: 12133261 [TBL] [Abstract][Full Text] [Related]
11. Laboratory markers and the risk of developing HIV-1 disease among injecting drug users. Alcabes P; Selwyn PA; Davenny K; Hartel D; Buono D; Schoenbaum EE; Klein RS; Friedland GH AIDS; 1994 Jan; 8(1):107-15. PubMed ID: 7912083 [TBL] [Abstract][Full Text] [Related]
12. Immunologic marker paths for seroconversion: single determinations of immunoglobulin A and beta 2-microglobulin are not adequate to estimate time of HIV infection. Multicohort Analysis Project Workshop. Part II. AIDS; 1994 Jul; 8(7):923-33. PubMed ID: 7946101 [TBL] [Abstract][Full Text] [Related]
13. Progression of HIV infection in misusers of injected drugs who stop injecting or follow a programme of maintenance treatment with methadone. Weber R; Ledergerber B; Opravil M; Siegenthaler W; Lüthy R BMJ; 1990 Dec; 301(6765):1362-5. PubMed ID: 1980219 [TBL] [Abstract][Full Text] [Related]
14. Markers for disease progression in intravenous drug users infected with HIV-1. Zangerle R; Fuchs D; Reibnegger G; Fritsch P; Wachter H AIDS; 1991 Aug; 5(8):985-91. PubMed ID: 1685652 [TBL] [Abstract][Full Text] [Related]
15. [Serum adenosine deaminase in human immunodeficiency virus infection. Its relationship with CD4+ lymphocytes and beta 2-microglobulin]. Iñigo MA; Ruiz López de Tejada M; Torres-Tortosa M; Sánchez-Porto A; Ugarte I; García de Lomas E; Morán Nestares A Med Clin (Barc); 1992 Dec; 99(20):766-8. PubMed ID: 1361013 [TBL] [Abstract][Full Text] [Related]
16. Neurologic and neuropsychological manifestations of human immunodeficiency virus infection in intravenous drug users without acquired immunodeficiency syndrome. Relationship to head injury. Marder K; Stern Y; Malouf R; Tang MX; Bell K; Dooneief G; el-Sadr W; Goldstein S; Gorman J; Richards M Arch Neurol; 1992 Nov; 49(11):1169-75. PubMed ID: 1444884 [TBL] [Abstract][Full Text] [Related]
17. HIV infection and cognition in intravenous drug users: long-term follow-up. Selnes OA; Galai N; McArthur JC; Cohn S; Royal W; Esposito D; Vlahov D Neurology; 1997 Jan; 48(1):223-30. PubMed ID: 9008522 [TBL] [Abstract][Full Text] [Related]
18. Clinical and laboratory predictors of survival in Gambian patients with symptomatic HIV-1 or HIV-2 infection. Whittle H; Egboga A; Todd J; Corrah T; Wilkins A; Demba E; Morgan G; Rolfe M; Berry N; Tedder R AIDS; 1992 Jul; 6(7):685-9. PubMed ID: 1354448 [TBL] [Abstract][Full Text] [Related]
19. Immunologic markers of AIDS progression: consistency across five HIV-infected cohorts. Multicohort Analysis Project Workshop. Part I. AIDS; 1994 Jul; 8(7):911-21. PubMed ID: 7946100 [TBL] [Abstract][Full Text] [Related]
20. Plasma levels of viro-immunological markers in HIV-infected and non-infected Ethiopians: correlation with cell surface activation markers. Messele T; Brouwer M; Girma M; Fontanet AL; Miedema F; Hamann D; Rinke de Wit TF Clin Immunol; 2001 Feb; 98(2):212-9. PubMed ID: 11161977 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]